ArticleAmerican journal of respiratory and critical care medicine2023

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One

Jennifer L Goralski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.